We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Cancer Genetics Expands Access to Proprietary Diagnostics Through Agreement with Harvard Pilgrim

By LabMedica International staff writers
Posted on 02 Aug 2015
Print article
Under the terms of a new agreement between Cancer Genetics, Inc. (CGI; Morrisville, NC, USA) and Harvard Pilgrim Healthcare (Hartford, CT; USA), a health care network covering over one million people throughout Massachusetts, Connecticut, and Maine, CGI will offer its cancer diagnostic services to individuals covered under Harvard Pilgrim plans.

Harvard Pilgrim's extensive provider network includes over 135 hospitals and 28,000 clinicians, among them physicians who practice in a variety of settings, including individual practices, small medical groups, and large multi-specialty groups. As part of the agreement, the Harvard Pilgrim’s network will have access to the full range of oncology-focused proprietary tests offered by CGI.

Working with provider networks is central to CGI's multipart access and reimbursement strategy. By establishing relationships with leading payers and insurance companies, CGI plans to expand access to and reimbursement for its leading-edge genomic tests to help providers appropriately manage and personalize treatment.

Cancer Genetics is an emerging leader in DNA-based cancer diagnostics, with tests that target difficult-to-diagnose hematological, urogenital, and HPV-associated cancers, designed to guide prognosis and treatment. Harvard Pilgrim's innovative approach to healthcare and collaboration with top institutions makes it a natural partner for Cancer Genetics.

"Cancer Genetics is very pleased to announce this relationship with Harvard Pilgrim Health Care. HPHC is one of the most respected health plan organizations in New England and is widely regarded for health care innovation, exceptional clinical quality and member satisfaction," said Randy Goodman, PhD, director of Reimbursement and Clinical Revenue Cycle Management, Cancer Genetics, "This agreement not only provides us with the opportunity to deliver services to a larger number of patients, but also allows us to work jointly with HPHC to help transform cancer patient management, increase treatment efficacy and reduce healthcare costs."

Related Links:

Cancer Genetics
Harvard Pilgrim Health Care 


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A massive study has identified new biomarkers for renal cancer subtypes, improving diagnosis and treatment (Photo courtesy of Jessica Johnson)

Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes

Renal cell carcinomas (RCCs) are notably diverse, encompassing over 20 distinct subtypes and generally categorized into clear cell and non-clear cell types; around 20% of all RCCs fall into the non-clear... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more